Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 2:12:7157-7164.
doi: 10.2147/OTT.S218001. eCollection 2019.

Significance of tertiary Gleason pattern 5 in patients with Gleason score 7 after radical prostatectomy: a retrospective cohort study

Jiakun Li  1 , Yaochuan Guo  2 , Shi Qiu  1 , Mingjing He  1 , Kun Jin  1 , Xiaonan Zheng  1 , Xiang Tu  1 , Xinyang Liao  1 , Lu Yang  1 , Qiang Wei  1
Affiliations

Significance of tertiary Gleason pattern 5 in patients with Gleason score 7 after radical prostatectomy: a retrospective cohort study

Jiakun Li et al. Onco Targets Ther. .

Abstract

Purpose: To evaluate the association between tertiary Gleason pattern 5 (TGP5) and biochemical recurrence (BCR) in patients with prostate cancer (PCa) with a Gleason score (GS) of 7 after radical prostatectomy (RP).

Patients and methods: This retrospective study identified 350 patients who received RP and were graded as GS 7 (3+4 or 4+3) at the West China Hospital from January 2009 to December 2017. Initially, the patients were divided into two groups, TGP5 absence and TGP5 presence, independent of Gleason score. We further stratified the patients by adding the Gleason score into four groups: GS 3+4, GS 3+4/TGP5, GS 4+3, and GS 4+3/TGP5. Cox proportional-hazards models were used to evaluate the association between the status of TGP5 and BCR after adjusting for the confounding factors.

Results: The risk of BCR was significantly higher in patients with TGP5 when compared to patients without TGP5 (P=0.04, HR=2.17 95%, Cl: 1.03-4.59). For patients with primary Gleason pattern 4, the risk of BCR for patients with Gleason 4+3/TGP5 was statistically significantly higher than Gleason 4+3 (P=0.04, HR=2.45, 95% Cl: 1.04-5.76).

Conclusion: The TGP5 in patients with GS 7 had strong association with the risk of BCR and was an independent predictor for BCR. Further research on larger data sets is needed to confirm these findings.

Keywords: Gleason score; biochemical recurrence; prostate cancer; radical prostatectomy; tertiary Gleason pattern.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Kaplan–Meier analysis of TGP5 absence and presence regardlessly the primary Gleason pattern. The survival probability of patients with TGP5 absence and presence.
Figure 2
Figure 2
Kaplan–Meier analysis of GS 4+3 and GS 4+3/TGP5. The survival probability of patients with GS 4+3 and GS 4+3/TGP5. The log-rank p=0.073.
Figure 3
Figure 3
Kaplan–Meier analysis of GS3+4 and GS3+4/TGP5. The survival probability of patients with GS3+4 and GS3+4/TGP5. There was no significant difference in BCR survival between patients with Gleason 3+4/TGP 5 compared to patients with Gleason 3+4 (log-rank P=0.73).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338 - DOI - PubMed
    1. Mottet N, Bellmunt J, Briers E, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Follow-up: after local treatment. Eur Urol. 2017;7(2):3. - PubMed
    1. Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996;20:286–292. doi:10.1097/00000478-199603000-00004 - DOI - PubMed
    1. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate- specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445–1451. - PubMed
    1. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol. 1998;160:2428. doi:10.1097/00005392-199809020-00019 - DOI - PubMed